Home > Dermatology > EADV 2019 > Spotlight on Psoriasis > Selective IL-23 blocker crushes fumaric acids in all assessed efficacy endpoints

Selective IL-23 blocker crushes fumaric acids in all assessed efficacy endpoints

Presented By
Prof. Diamant Thaçi, University of Lübeck, Germany
Conference
EADV 2019
A head-to-head comparison of the selective IL-23 blocker risankizumab with oral fumaric acid esters in treatment-naïve patients with moderate-to-severe psoriasis demonstrated superiority of the biologic in all assessed efficacy endpoints at week 24 [1]. In the Netherlands, Germany, the United Kingdom, and Ireland, fumaric acid esters are frequently used for systemic therapy of moderate-to-severe psoriasis [2-4]. A new head-to-head trial included systemic treatment-naïve adult patients with chronic moderate-to-severe plaque psoriasis of at least 6 months duration. All patients qualified for systemic therapy: they had a psoriasis area and severity index score >10, an affected body surface area of >10%, and their quality of life was severely impaired (dermatology life quality index score of >10). Patients were randomised to receive subcutaneous risankizumab 150 mg at weeks 0, 4, and 16 (n=60) or oral fumaric acid esters in increasing doses from week ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on